Jasper Therapeutics Inc expected to post a loss of $1.26 a share - Earnings Preview

Reuters02-28

<a href="https://laohu8.com/S/JSPR">Jasper Therapeutics</a> Inc <jspr.oq> expected to post a loss of $1.26 a share - Earnings Preview </jspr.oq>

Jasper Therapeutics Inc JSPR.OQ JSPR.O is expected to show no change in quarterly revenue when it reports results on May 12 (estimated) for the period ending March 31 2025
LSEG's mean analyst estimate for Jasper Therapeutics Inc is for a loss of $1.26 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts had risen by about 0.5% in the last three months.
Wall Street's median 12-month price target for Jasper Therapeutics Inc is $64.00, above its last closing price of $5.67.

Previous quarterly performance (using preferred earnings measure in US dollars).

QUARTER ENDING	STARMINESMARTESTIMATE®	LSEG IBES ESTIMATE	ACTUAL	BEAT, MET, MISSED	SURPRISE %
Dec. 31 2024	-1.23	-1.23	-1.62	Missed	-31.7
Sep. 30 2024	-1.08	-1.07	-1.24	Missed	-15.7
Jun. 30 2024	-1.08	-1.09	-0.97	Beat	10.9
Mar. 31 2024	-1.23	-1.22	-1.03	Beat	15.9
Dec. 31 2023	-1.60	-1.61	-1.50	Beat	7.1
Sep. 30 2023	-1.53	-1.55	-1.60	Missed	-3.1
Jun. 30 2023	-1.81	-1.50	-1.50	Met	-0.1
Mar. 31 2023	-1.64	-1.62	-1.60	Beat	1.5

This summary was machine generated February 28 at 14:19 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2514279533?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-28 22:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2514279533","market":"nz","top_or_hot":-1,"title":"Jasper Therapeutics Inc  expected to post a loss of $1.26 a share - Earnings Preview","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/JSPR\">Jasper Therapeutics</a> Inc <jspr.oq> expected to post a loss of $1.26 a share - Earnings Preview </jspr.oq></title></head><body><ul><li><p>Jasper <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <span>JSPR.OQ</span> <span>JSPR.O</span> is expected to show no change in quarterly revenue when it reports  results on May 12 (estimated) for the period ending March 31 2025</p></li><li></li><li><p>LSEG's mean analyst estimate for Jasper Therapeutics Inc is for a loss of $1.26 per share. </p></li><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 12 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\"  </p></li><li><p>The mean earnings estimate of analysts had risen by about 0.5% in the last three months. </p></li><li><p>Wall Street's median 12-month price target for Jasper Therapeutics Inc is $64.00, above its last closing price of $5.67. </p></li></ul><p>Previous quarterly performance (using preferred earnings measure in US dollars). </p><table><tbody><tr><td><p>QUARTER ENDING</p></td><td><p>STARMINESMARTESTIMATE®</p></td><td><p>LSEG IBES ESTIMATE </p></td><td><p>ACTUAL</p></td><td><p>BEAT, MET, MISSED</p></td><td><p>SURPRISE %</p></td></tr><tr><td><p>Dec. 31 2024</p></td><td><p>-1.23</p></td><td><p>-1.23</p></td><td><p>-1.62</p></td><td><p>Missed</p></td><td><p>-31.7</p></td></tr><tr><td><p>Sep. 30 2024</p></td><td><p>-1.08</p></td><td><p>-1.07</p></td><td><p>-1.24</p></td><td><p>Missed</p></td><td><p>-15.7</p></td></tr><tr><td><p>Jun. 30 2024</p></td><td><p>-1.08</p></td><td><p>-1.09</p></td><td><p>-0.97</p></td><td><p>Beat</p></td><td><p>10.9</p></td></tr><tr><td><p>Mar. 31 2024</p></td><td><p>-1.23</p></td><td><p>-1.22</p></td><td><p>-1.03</p></td><td><p>Beat</p></td><td><p>15.9</p></td></tr><tr><td><p>Dec. 31 2023</p></td><td><p>-1.60</p></td><td><p>-1.61</p></td><td><p>-1.50</p></td><td><p>Beat</p></td><td><p>7.1</p></td></tr><tr><td><p>Sep. 30 2023</p></td><td><p>-1.53</p></td><td><p>-1.55</p></td><td><p>-1.60</p></td><td><p>Missed</p></td><td><p>-3.1</p></td></tr><tr><td><p>Jun. 30 2023</p></td><td><p>-1.81</p></td><td><p>-1.50</p></td><td><p>-1.50</p></td><td><p>Met</p></td><td><p>-0.1</p></td></tr><tr><td><p>Mar. 31 2023</p></td><td><p>-1.64</p></td><td><p>-1.62</p></td><td><p>-1.60</p></td><td><p>Beat</p></td><td><p>1.5</p></td></tr></tbody></table><p>This summary was machine generated February 28 at 14:19 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jasper Therapeutics Inc  expected to post a loss of $1.26 a share - Earnings Preview</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJasper Therapeutics Inc  expected to post a loss of $1.26 a share - Earnings Preview\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-02-28 22:19</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/JSPR\">Jasper Therapeutics</a> Inc <jspr.oq> expected to post a loss of $1.26 a share - Earnings Preview </jspr.oq></title></head><body><ul><li><p>Jasper <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <span>JSPR.OQ</span> <span>JSPR.O</span> is expected to show no change in quarterly revenue when it reports  results on May 12 (estimated) for the period ending March 31 2025</p></li><li></li><li><p>LSEG's mean analyst estimate for Jasper Therapeutics Inc is for a loss of $1.26 per share. </p></li><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 12 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\"  </p></li><li><p>The mean earnings estimate of analysts had risen by about 0.5% in the last three months. </p></li><li><p>Wall Street's median 12-month price target for Jasper Therapeutics Inc is $64.00, above its last closing price of $5.67. </p></li></ul><p>Previous quarterly performance (using preferred earnings measure in US dollars). </p><table><tbody><tr><td><p>QUARTER ENDING</p></td><td><p>STARMINESMARTESTIMATE®</p></td><td><p>LSEG IBES ESTIMATE </p></td><td><p>ACTUAL</p></td><td><p>BEAT, MET, MISSED</p></td><td><p>SURPRISE %</p></td></tr><tr><td><p>Dec. 31 2024</p></td><td><p>-1.23</p></td><td><p>-1.23</p></td><td><p>-1.62</p></td><td><p>Missed</p></td><td><p>-31.7</p></td></tr><tr><td><p>Sep. 30 2024</p></td><td><p>-1.08</p></td><td><p>-1.07</p></td><td><p>-1.24</p></td><td><p>Missed</p></td><td><p>-15.7</p></td></tr><tr><td><p>Jun. 30 2024</p></td><td><p>-1.08</p></td><td><p>-1.09</p></td><td><p>-0.97</p></td><td><p>Beat</p></td><td><p>10.9</p></td></tr><tr><td><p>Mar. 31 2024</p></td><td><p>-1.23</p></td><td><p>-1.22</p></td><td><p>-1.03</p></td><td><p>Beat</p></td><td><p>15.9</p></td></tr><tr><td><p>Dec. 31 2023</p></td><td><p>-1.60</p></td><td><p>-1.61</p></td><td><p>-1.50</p></td><td><p>Beat</p></td><td><p>7.1</p></td></tr><tr><td><p>Sep. 30 2023</p></td><td><p>-1.53</p></td><td><p>-1.55</p></td><td><p>-1.60</p></td><td><p>Missed</p></td><td><p>-3.1</p></td></tr><tr><td><p>Jun. 30 2023</p></td><td><p>-1.81</p></td><td><p>-1.50</p></td><td><p>-1.50</p></td><td><p>Met</p></td><td><p>-0.1</p></td></tr><tr><td><p>Mar. 31 2023</p></td><td><p>-1.64</p></td><td><p>-1.62</p></td><td><p>-1.60</p></td><td><p>Beat</p></td><td><p>1.5</p></td></tr></tbody></table><p>This summary was machine generated February 28 at 14:19 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"JSPR","symbol_name":"Jasper Therapeutics","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nL5N3PJ1JU:1","article_id":"2514279533","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2514279533","pubTimestamp":1740752346,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Jasper Therapeutics Inc  expected to post a loss of $1.26 a share - Earnings Preview Jasper Therapeutics Inc JSPR.OQ JSPR.O is expected to show no change in quarterly revenue when it reports  results ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"JSPR":"Jasper Therapeutics"},"translate_title":"Jasper Therapeutics Inc预计每股亏损1.26美元-收益预览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JSPR":0.9},"content_text":"Jasper Therapeutics Inc  expected to post a loss of $1.26 a share - Earnings Preview Jasper Therapeutics Inc JSPR.OQ JSPR.O is expected to show no change in quarterly revenue when it reports  results on May 12 (estimated) for the period ending March 31 2025LSEG's mean analyst estimate for Jasper Therapeutics Inc is for a loss of $1.26 per share. The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 12 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\"  The mean earnings estimate of analysts had risen by about 0.5% in the last three months. Wall Street's median 12-month price target for Jasper Therapeutics Inc is $64.00, above its last closing price of $5.67. Previous quarterly performance (using preferred earnings measure in US dollars). QUARTER ENDINGSTARMINESMARTESTIMATE®LSEG IBES ESTIMATE ACTUALBEAT, MET, MISSEDSURPRISE %Dec. 31 2024-1.23-1.23-1.62Missed-31.7Sep. 30 2024-1.08-1.07-1.24Missed-15.7Jun. 30 2024-1.08-1.09-0.97Beat10.9Mar. 31 2024-1.23-1.22-1.03Beat15.9Dec. 31 2023-1.60-1.61-1.50Beat7.1Sep. 30 2023-1.53-1.55-1.60Missed-3.1Jun. 30 2023-1.81-1.50-1.50Met-0.1Mar. 31 2023-1.64-1.62-1.60Beat1.5This summary was machine generated February 28 at 14:19 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2514279533","isCrawlerRequest":true}